Roche's Chugai has filed a patent lawsuit against Alexion for allegedly infringing on the technology used in Alexion's Ultomiris, which is indicated for the treatment of atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. At issue is technology that reduces Ultomiris' typical dosing to once every eight weeks from predecessor Soliris' biweekly dosing.
Roche's Chugai sues Alexion to block launch of Ultomiris
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.